Mark Murphy, MD
Addiction Medicine · Gig Harbor, WANPI 1740294818
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (55.5%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. Indivior Inc. accounts for 91.5% of it on its own, with 17 other manufacturers making up the rest. 2025 is the largest year on record at $16,628, more than ten times the $660 reported in 2019. Among addiction medicine clinicians in WA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 139 payments — averaging $157.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Indivior Inc.$20K
- AbbVie$381
- Collegium Pharmaceutical, Inc.$326
- Braeburn Inc.$193
- Orexo US, Inc.$185
- Alkermes, Inc.$176
- plus $604 from 12 others
What the payments were for
- Consulting fees$1,0135%
- Speaking & faculty fees$12,11956%
- Travel & lodging$5,25424%
- Food & beverage$3,38115%
- Education$580%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Indivior Inc. | 67 | $19,961 |
| AbbVie(2 entities) | 5 | $381 |
| Collegium Pharmaceutical, Inc. | 21 | $326 |
| Braeburn Inc. | 5 | $193 |
| Orexo US, Inc. | 11 | $185 |
| Alkermes, Inc. | 4 | $176 |
| Biomarin Pharmaceutical Inc. | 1 | $129 |
| Amgen | 4 | $78 |
| Lilly USA, LLC | 3 | $70 |
| Daiichi Sankyo Inc. | 3 | $68 |
| Boehringer Ingelheim | 3 | $64 |
| Pfizer | 3 | $45 |
| Biodelivery Sciences International, Inc. | 3 | $41 |
| MDD US Operations, LLC | 2 | $36 |
| Johnson & Johnson | 1 | $23 |
| Astellas Pharma US Inc | 1 | $23 |
| Merck | 1 | $14 |
| Sanofi-aventis U.S. LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$21,825 in reported general payments places this provider in the 95th percentile of 39 addiction medicine providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Xtampza ErOxycodone Myristate | 72 | $45,232 |
| BrixadiBuprenorphine | 13 | $22,493 |
| VivitrolNaltrexone Microspheres | 13 | $20,994 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 145 | $17,005 |
| SuboxoneBuprenorphine Hcl/Naloxone Hcl | 19 | $15,200 |
| OxycontinOxycodone Hcl | 21 | $12,103 |
| Buprenorphine | 49 | $10,208 |
| Oxycodone Hcl | 234 | $6,564 |
| Lisdexamfetamine Dimesylate | 15 | $4,575 |
| Fentanyl | 38 | $4,286 |
| Buprenorphine Hcl | 52 | $1,922 |
| Methadone Hcl | 71 | $1,891 |
| Morphine Sulfate ErMorphine Sulfate | 38 | $1,639 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 19 | $1,266 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 38 | $1,132 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Collegium Pharmaceutical, Inc.Xtampza Er | $326 | $45,23272 claims |
| Braeburn Inc.Brixadi | $193 | $22,49313 claims |
| Alkermes, Inc.Vivitrol | $176 | $20,99413 claims |
| Indivior Inc.Suboxone | $19,961 | $15,20019 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 39 addiction medicine providers in Washington.
Other addiction medicine in Gig Harbor
- Amy MaherGig Harbor$118
- Amanda WilsonGig Harbor$103
- John PatzMonroe$12K
- Joy Ruiz-MollestonLakewood$6K
- Cirilo AdaoLakewood$3K
- David CundiffLong Beach$977
- Jeffrey AllgaierRichland$762
- Tarek HaidarTacoma$758
- Elina ChernyakClarkston$612
- Phyllis HendersonYakima$566
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.